To include your compound in the COVID-19 Resource Center, submit it here.

BioTime reports Phase I/IIa data for dry AMD candidate

BioTime Inc. (NYSE-M:BTX; Tel Aviv:BTX) reported data from 6 evaluable patients with dry age-related macular degeneration (AMD) in a Phase I/IIa

Read the full 212 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE